PI3K inhibitors for cancer treatment: where do we stand?

Biochemical Society Transactions
Sauveur-Michel MairaCarlos García-Echeverría

Abstract

In contrast with cytotoxic agents that do not differentiate between normal proliferating and tumour cells, targeted therapies primarily exert their actions in cancer cells. Initiation and maintenance of tumours are due to genetic alterations in specific loci. The identification of the genes in which these alterations occur has opened new opportunities for cancer treatment. The PI3K (phosphoinositide 3-kinase) pathway is often overactive in human cancers, and various genetic alterations have been found to cause this. In all cases, PI3K inhibition is considered to be one of the most promising targeted therapies for cancer treatment. The present mini-review provides an update on new PI3K inhibitors currently in or entering clinical development. Recent discoveries, challenges and future prospects will be discussed.

References

Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·K PodsypaninaR Parsons
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·M S NeshatC L Sawyers
Jan 18, 2005·Trends in Biochemical Sciences·Laura S HarringtonRichard F Lamb
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen ChanLaurence Moore
Jun 22, 2005·Neoplasia : an International Journal for Oncology Research·Bénédicte F JordanRobert J Gillies
Jul 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evanthia GalanisUNKNOWN North Central Cancer Treatment Group
Dec 13, 2005·Nature Medicine·George V ThomasCharles L Sawyers
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Apr 20, 2006·Journal of the National Cancer Institute·Shin-ichi YaguchiTakao Yamori
May 16, 2006·Cancer Cell·Qi-Wen FanWilliam A Weiss
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Federico RojoSantiago Ramon y Cajal
Feb 17, 2007·The Biochemical Journal·Severine I GharbiMichael D Waterfield
Mar 17, 2007·The Biochemical Journal·Claire ChaussadePeter R Shepherd
Mar 21, 2007·Biochemical Society Transactions·Z A Knight, K M Shokat
Mar 27, 2007·Pharmaceutical Research·Renu M Stephen, Robert J Gillies
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Nov 13, 2007·Biochimica Et Biophysica Acta·Romina MaroneMatthias P Wymann
Dec 22, 2007·Nature Reviews. Cancer·Roberto ChiarleGiorgio Inghirami
Feb 6, 2008·Bioorganic & Medicinal Chemistry Letters·Frédéric StaufferCarlos García-Echeverría
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chiaki TanakaHeidi A Lane
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroJosé Baselga
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne O'DonnellIan Judson
Mar 14, 2008·Nature·Heather R ChristofkLewis C Cantley
Mar 18, 2008·Nature·Kian-Huat LimChristopher M Counter
May 8, 2008·Cell Metabolism·Pawan GulatiGeorge Thomas
May 10, 2008·The Biochemical Journal·Jingxiang Huang, Brendan D Manning
Jul 16, 2008·Proceedings of the National Academy of Sciences of the United States of America·Tina L YuanLewis C Cantley

❮ Previous
Next ❯

Citations

Aug 25, 2009·Breast Cancer Research and Treatment·Mohammed A AleskandaranyAndrew R Green
Jan 25, 2013·Molecular Therapy. Nucleic Acids·Sateesh KrishnamurthyBeverly L Davidson
Mar 25, 2010·Nature Reviews. Cancer·Deborah SilveraRobert J Schneider
Jan 9, 2013·Rheumatology·Victoria Kelly, Mark Genovese
Mar 24, 2011·Future Medicinal Chemistry·Abhijit RoychowdhurySanjay Kumar
Feb 18, 2016·Cancer Immunology, Immunotherapy : CII·Davide BommaritoRoberto Bellucci
Jan 29, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emma J HaagensenDavid R Newell
Sep 14, 2012·Expert Opinion on Drug Discovery·Paul Bamborough
Jan 26, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Raphael S PeresFernando Q Cunha
Dec 20, 2011·Trends in Molecular Medicine·Stephanie Alexander, Peter Friedl
Jun 1, 2011·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Chen SunXiangdong Wang
Dec 25, 2015·Vascular Pharmacology·Arturo GiordanoMaria Fiammetta Romano
Apr 21, 2012·British Journal of Pharmacology·Stuart P AtkinsonLyle Armstrong
Dec 23, 2009·International Journal of Cancer. Journal International Du Cancer·Ruth ChuSylvia Fong
Jul 16, 2010·Cardiovascular Therapeutics·Andreas Eisenreich, Ursula Rauch
Jul 14, 2009·Biochemical and Biophysical Research Communications·Stanley K L NgEe-Chee Ren
Jul 22, 2014·British Journal of Pharmacology·Peter LanzerstorferJulian Weghuber
Oct 7, 2011·Platelets·T LhermusierB Payrastre
Feb 1, 2015·Experimental Cell Research·Olga MartinhoRui Manuel Reis
Jan 22, 2015·Neuro-oncology·Marshall W PitzWarren P Mason
Nov 12, 2016·Cancer Chemotherapy and Pharmacology·Emma J HaagensenDavid R Newell
Jul 17, 2010·Yonsei Medical Journal·Dan Richard LaksHarley Ian Kornblum
Feb 2, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Fraser R MillarAdam Giangreco
Mar 15, 2012·British Journal of Cancer·E J HaagensenD R Newell
Jan 16, 2009·Biochemical Society Transactions·Deborah C I Goberdhan, C A Richard Boyd

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.